Bio-Techne TECH · USD
Health Care · Life Sciences Tools & Services · US listing · 🇺🇸 United States
S&P 500
72.83
+0.07%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Bio-Techne
From its filings with the US Securities and Exchange Commission
Bio-Techne is based in Minneapolis, Minnesota and is incorporated in Minnesota. Its shares trade on Nasdaq under the ticker TECH. It is a member of the S&P 500. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 30 June 2026, it reported revenue of $1.22bn. At that date it held total assets of $2.59bn and shareholders' equity of $2.11bn.
Bio-Techne and its subsidiaries, collectively doing business as Bio-Techne Corporation (“Bio-Techne”, “we”, “our”, “us” or the “Company”), develop, manufacture and sell life science reagents, instruments and services for the research, diagnostics and bioprocessing markets worldwide. Our broad product portfolio and application expertise enables scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. Our products aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses.
We manage the business in two operating segments – our Protein Sciences segment and our Diagnostics and Spatial Biology segment. Our Protein Sciences segment is a leading developer and manufacturer of high-quality biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. This segment also includes proteomic analytical tools, both manual and automated, that offer researchers and pharmaceutical manufacturers efficient and streamlined options for protein analysis, automated western blot, and multiplexed ELISA workflows. Our Diagnostics and Spatial Biology segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, advanced tissue-based in-situ hybridization assays and instrumentation for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications.
Quoted from its 10-K, filed 24 Aug 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 9 Feb 1989
- Employees
- 3,100
- Website
- bio-techne.com ↗
- Head office
- 614 MCKINLEY PLACE NE, MINNEAPOLIS, MN
- Incorporated in
- MN
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. Robert BaumgartnerIndependent Chairman of the Board$400,422
- Mr. Kim KeldermanPresident, Chief Executive Officer, Director, since 2018$8.2m
- Mr. James HippelChief Financial Officer, Executive Vice President - Finance$7.0m
- Mr. William GeistPresident - Protein Sciences$3.1m
- Dr. Matthew McmanusPresident - Diagnostics and Spatial Biology$2.8m
- Mr. Shane BohnenSenior Vice President, General Counsel, Corporate Secretary$2.0m
- Ms. Julie BushmanIndependent Director$292,922
- Dr. Amy HerrIndependent Director$181,360
- Mr. John HigginsIndependent Director$300,422
- Dr. Joseph KeeganIndependent Director$275,422
- Dr. Judith KlimovskyIndependent Director$275,346
- Dr. Roeland NusseIndependent Director$290,422
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 72
- Environment
- 58
- Social
- 99
- Governance
- 59
- Women in the workforce
- 49%
- Carbon reduction policy
- No
- Human rights policy
- Yes
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.